Scientific Library
Article
HDACs: Active drug targets for Immunotherapy treatment
June 13, 2018
For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development.